Skip to main content
. 2022 Dec;63(12):1891–1898. doi: 10.2967/jnumed.122.263823

FIGURE 4.

FIGURE 4.

Response assessment of target liver lesions at 3 and 6 mo after treatment with 166Ho-microsphere radioembolization according to mRECIST. Some patients did not undergo imaging at 3- or 6-mo follow-up because of death (n = 2 and 8, respectively) or withdrawn consent (n = 2 or 0, respectively). Some patients were not evaluable because of absence of arterial enhancement of tumor or low-quality imaging (e.g., artifacts or breathing motion) (n = 3 and 2, respectively).